Indication
Nasal and Nasal-Type
3 clinical trials
8 products
Clinical trial
Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell LymphomaStatus: Completed, Estimated PCD: 2022-12-30
Product
TislelizumabClinical trial
A Phase Ib/II Clinical Trial of Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaStatus: Recruiting, Estimated PCD: 2026-10-31
Product
LinperlisibProduct
CamrelizumabProduct
PegaspargaseProduct
DexamethasoneClinical trial
A Multicenter, Randomized, Controlled Phase II Screening Study of Combined Sequential Chemotherapy and Radiation Therapies for Early-stage Natural Killer/T-cell Lymphoma (IE/IIE)Status: Recruiting, Estimated PCD: 2026-12-30
Product
Sintilimab+PegaspargaseProduct
P-GemOxProduct
GELAD